STAMPEDE

Understanding the Recent Advances in Treating Castrate Sensitive Prostate Cancer 

Understanding the Recent Advances in Treating Castrate Sensitive Prostate Cancer 

Abiraterone, enzalutamide, apalutamide, and docetaxel could be considered for this patient population (castrate sensitive prostate cancer patients), noted Taplin. "None of us can [confirm] that one [option] is better than the other; [the treatment decision] needs to be individualized [by weighing the] pros and cons [with each agent] for each patient," Taplin concluded.

Survival Not Improved by Adding Radiotherapy in All Newly Diagnosed Men with Metastatic Prostate Cancer

According to the results of the STAMPEDE trial.1 adding radiotherapy (radiation) to the current standard-of-care androgen deprivation therapy (ADT of hormone therapy) did not improve the overall survival in all men who are newly diagnosed metastatic prostate cancer.   

Ablative Radiation Increases Survival in Some Newly Diagnosed Men with Metastatic Prostate Cancer

In certain men newly diagnosed with Advanced Prostate Cancer, or metastatic prostate cancer debunking the tumor with radiation can increase survival advantage.